Neomics announces appointment of Dr. Kim Sun-kyu as new director

Neomix Co., a local biopharmaceutical firm, has recently announced the appointment of Dr. Kim Sun-kyu (40 years old, photo) as its new director during the shareholder meeting, under the recommendation of Novartis Korea and Norvatis Venture Fund.

Nornatis AG targeted its first Korean biotechnology start-up for investment. Neomics was selected as the first recipient of the Norvatis Venture Fun...